肿瘤研究所公司 2025年季度报告

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for suchshorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.YesýNo☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesýNo☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of“large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.: Yes☐Noý Table of Contents Note: The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). The condensed consolidated balance sheets includetotal assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $72,247and $70,804as of March31, 2025 and December31, 2024, respectively, and total liabilities ofthe Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaling $277,056and $274,001as of March31, 2025 and December31, 2024,respectively. See Note 16 for further details. THE ONCOLOGY INSTITUTE, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(US Dollars in thousands, except share data) THE ONCOLOGY INSTITUTE, INC.CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND CHANGES IN STOCKHOLDERS’ EQUITY THE ONCOLOGY INSTITUTE, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(US Dollars in thousands)(Unaudited) THE ONCOLOGY INSTITUTE, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)As of March31, 2025 and December31, 2024, and for the threemonths endedMarch31, 2025 and 2024(US Dollars in thousands, except share data) Note 1.Description of the Business Overview of the Business The Oncology Institute, Inc. (“TOI”),originally founded in 2007, is a leading, national platform delivering integrated direct care and cost management to patients and payors who are experiencingor managing members undergoing treatment for cancer and other complex medical conditions. Through wholly-owned subsidiaries and affiliated entities, TOI operates combined community clinics and infusion suites staffed with providers who administer latest-generation cancer treatmentsincluding chemotherapy, immunotherapy, oncolytics, and radiation oncology. Additionally, TOI provides coordinated case management, drug formulary management, and fully-delegated networks ofcare providers, all of which we use to drive improved treatment outcomes at the lowest possible cost to our patients and payors. Additionally, TOI operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by our patients concurrent with their in-office cancer therapies. Given the scale, breadth, and depth of our The Company has121oncologists and mid-level professionals across67clinic locations located withinfivestates: California, Florida, Arizona, Oregon and Nevada. The Company has contractualrelationships with multiple payors, serving Medicare, including Medicare Advantage, Medi-Cal, and commercial patients. Note 2.Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying interim condensed consolidated financial statements are unaudited and have been prepared in accordance with Article 10 of Regulation S-X issued by the U.S. Securities andExchange Commission ("SEC"). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles ("GAAP") for completeconsolidated financial statements. However, the Company believes that the disclosures are adequate to ensure the information is not misleading. In the opinion of management, all adjustments (of normal Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of TOI, its subsidiaries, all of which are controlled by TOI through majority voting control, and variableinterest entities (“VIEs”) for which TOI (through TOI Management) is the primary beneficiary. The Company consolidates entities in which it has a controlling financial interest based on either thevariable interest entity or voting interest model. All significant intercompany balances and transactions have been eliminated in consolidation. Variable Interest Entities The Company consolidates entities